儿童地方性与散发性伯基特淋巴瘤体细胞编码区及非编码区突变的基因组范围发现
本研究对儿童地方性与散发性伯基特淋巴瘤(BL)进行全基因组和转录组整合分析,发现EBV阳性肿瘤全基因组异常体细胞超突变增加,提示EBV与AICDA活性相关。EBV阳性肿瘤驱动突变显著更少,尤其凋亡相关基因,并发现IGHV4-34、IGKV3-20等免疫球蛋白可变区基因被不成比例地用于编码克隆性BCR。结果显示肿瘤EBV状态界定特定BL表型,与地理来源无关。
要点
- EBV阳性肿瘤全基因组异常体细胞超突变增加,支持EBV与AICDA活性相关
- EBV阳性肿瘤驱动突变显著更少,尤其凋亡相关基因
- IGHV4-34与IGKV3-20被不成比例用于编码克隆性BCR
核心结论
- 肿瘤EBV状态界定特定BL表型,与地理来源无关,具有特定分子特征和不同致病机制
- 新突变模式提示部分BL患者可合理使用DNA损伤性化疗,另一些可考虑靶向药物如CDK4/6抑制剂palbociclib
- BCR信号在BL中的重要性强化了PI3K、Syk和Src家族激酶抑制剂在这些患者中的潜在获益
研究设计与样本
- 通过全基因组和转录组数据整合分析,评估肿瘤EBV状态或地理来源相关的BL分子特征
- 研究对象为儿童地方性与散发性伯基特淋巴瘤
主要发现
- EBV阳性肿瘤全基因组异常体细胞超突变显著增加
- EBV阳性肿瘤驱动突变显著更少,尤其凋亡相关基因
- 发现新候选BL基因SIN3A、USP7和CHD8
- IGHV4-34被不成比例用于编码克隆性BCR,已知可产生自身反应性抗体
- IGKV3-20被不成比例用于编码克隆性BCR,见于其他B细胞恶性肿瘤但尚未在BL中描述
关键数值与推荐
- EBV阳性在疟疾流行区超过90%病例,其他地区高达30%
- 原文未报告具体驱动突变数量、超突变数值及统计学参数
临床怎么用
- 作者认为新突变模式提示部分BL患者可合理使用DNA损伤性化疗,另一些可考虑CDK4/6抑制剂palbociclib等靶向药物
- 作者认为BCR信号在BL中的重要性强化了PI3K、Syk和Src家族激酶抑制剂的潜在获益
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although generally curable with intensive chemotherapy in resource-rich settings, Burkitt lymphoma (BL) remains a deadly disease in older patients and in sub-Saharan Africa. Epstein-Barr virus (EBV) positivity is a feature in more than 90% of cases in malaria-endemic regions, and up to 30% elsewhere. However, the molecular features of BL have not been comprehensively evaluated when taking into account tumor EBV status or geographic origin. Through an integrative analysis of whole-genome and transcriptome data, we show a striking genome-wide increase in aberrant somatic hypermutation in EBV-positive tumors, supporting a link between EBV and activation-induced cytidine deaminase (AICDA) activity. In addition to identifying novel candidate BL genes such as SIN3A, USP7, and CHD8, we demonstrate that EBV-positive tumors had significantly fewer driver mutations, especially among genes with roles in apoptosis. We also found immunoglobulin variable region genes that were disproportionally used to encode clonal B-cell receptors (BCRs) in the tumors. These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL. Our results suggest that tumor EBV status defines a specific BL phenotype irrespective of geographic origin, with particular molecular properties and distinct pathogenic mechanisms. The novel mutation patterns identified here imply rational use of DNA-damaging chemotherapy in some patients with BL and targeted agents such as the CDK4/6 inhibitor palbociclib in others, whereas the importance of BCR signaling in BL strengthens the potential benefit of inhibitors for PI3K, Syk, and Src family kinases among these patients.
引用
- Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019. PMID: 30617194. doi:10.1182/blood-2018-09-871418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。